ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $305,203 | -59.1% | 57,477 | -26.6% | 0.00% | -100.0% |
| Q2 2023 | $745,932 | +91.0% | 78,272 | +120.5% | 0.00% | – |
| Q1 2023 | $390,467 | -25.7% | 35,497 | +0.0% | 0.00% | -100.0% |
| Q4 2022 | $525,193 | -21.0% | 35,486 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $665,000 | +75.9% | 34,853 | +96.5% | 0.00% | – |
| Q2 2022 | $378,000 | +14.2% | 17,741 | +2.9% | 0.00% | – |
| Q1 2022 | $331,000 | -9.6% | 17,239 | -2.3% | 0.00% | – |
| Q4 2021 | $366,000 | -63.9% | 17,643 | -58.5% | 0.00% | – |
| Q3 2021 | $1,015,000 | +153.8% | 42,491 | +190.6% | 0.00% | – |
| Q2 2021 | $400,000 | -17.0% | 14,624 | -12.3% | 0.00% | – |
| Q1 2021 | $482,000 | -30.3% | 16,677 | -32.3% | 0.00% | – |
| Q4 2020 | $692,000 | – | 24,618 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |